Public Summary

Summary for ARTG Entry:	314807 METAGENICS SULFORACLEAR
ARTG entry for	Medicine Listed
Sponsor	Metagenics (Aust) Pty Ltd
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia
ARTG Start Date	26/02/2019
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS SULFORACLEAR

Product Type Single Medicine Product **Effective Date** 26/02/2019

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Aids/assists natural body cleansing/detoxification processes

Indication Requirements

Product presentation must not imply or refer to drugs/alcohol.

Product presentation must only refer to detoxification in relation to natural body processes.

Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Active Ingredients	
Brassica oleracea var. italica seed Extract dry concentrate	**200 mg**
Equivalent: Brassica oleracea var. italica (Dry)	2 g
Brassica oleracea var. italica sprout Powder	**200 mg**
calcium ascorbate dihydrate	**96 mg**
Equivalent: ascorbic acid	80 mg

Other Ingredients (Excipients)

disodium edetate
gellan gum
hyprolose
hypromellose
magnesium stearate
microcrystalline cellulose
potable water
potassium acetate
silicon dioxide
tartaric acid

Public Summary